LIPELLA PHARMACEUTICALS INC (LIPO) Stock News

NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD

2.36 -0.35 (-12.75%)

After market: 1.8001 -0.56 (-23.72%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LIPO Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: SPTN IBO CMPS CDTX ...

Crude Oil Falls 1%; US Services PMI Declines In June

a month ago - By: Benzinga - Mentions: FDS SANW IBO CMPS ...

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

a month ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

2 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

9 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

2 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

3 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

3 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

4 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

4 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

5 months ago - By: Spartan Capital Securities, LLC - Mentions: HCTI

Spartan Capital Securities, LLC Announces Key February Transactions

5 months ago - By: Spartan Capital Securities, LLC

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

6 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

6 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

7 months ago - By: Spartan Capital Securities, LLC

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

8 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

8 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

9 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

9 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference